OTIC · Otonomy, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | - | - | $35.0K | $90.0K | - | $50.0K | $10.0K |
| Cost of Revenue | $0 | $0 | $0 | - | - | $140.0K | $230.0K | - | $189.0K | $511.0K |
| Gross Profit | $0 | $0 | $0 | - | - | ($105.0K) | ($140.0K) | - | ($139.0K) | ($501.0K) |
| R&D | $8.41M | $9.23M | $9.41M | - | $8.98M | $8.36M | $7.66M | - | $7.02M | $6.93M |
| SG&A | $3.43M | $3.52M | $3.75M | - | $3.50M | $3.67M | $4.04M | - | $3.36M | $3.68M |
| Total Operating Expenses | $11.84M | $12.76M | $13.15M | - | $12.48M | $12.17M | $11.93M | - | $10.57M | $11.13M |
| D&A | - | - | $195.0K | - | - | - | $221.0K | - | - | - |
| Operating Income | ($11.84M) | ($12.76M) | ($13.15M) | - | ($12.48M) | ($12.13M) | ($11.84M) | - | ($10.52M) | ($11.12M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($12.05M) | ($13.08M) | ($13.55M) | - | ($12.88M) | ($12.51M) | ($12.21M) | - | ($10.87M) | ($11.45M) |
| EPS - Basic | ($0.19) | ($0.19) | - | - | - | - | - | - | - | - |
| EPS - Diluted | ($0.18) | ($0.19) | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $40.15M | $53.15M | $62.87M | $77.41M | $81.84M | $85.10M | $51.02M | $30.77M | $54.23M | $32.05M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | $455.0K | $227.0K | - | - |
| Accounts Payable | $616.0K | $2.19M | $1.45M | $1.09M | $467.0K | $1.26M | $573.0K | $849.0K | $510.0K | $665.0K |
| Current Assets | $43.91M | $56.35M | $66.38M | $80.47M | $89.29M | $99.35M | $76.88M | $88.72M | $97.29M | $42.60M |
| Total Assets | $57.53M | $70.76M | $81.23M | $95.64M | $104.88M | $115.42M | $93.41M | $106.27M | $115.31M | $61.23M |
| Current Liabilities | $25.25M | $11.66M | $10.04M | $12.33M | $9.74M | $8.83M | $10.70M | $10.99M | $10.84M | $11.32M |
| Long-term Debt | $0 | $15.63M | $16.04M | $16.00M | $15.96M | $15.91M | $13.25M | $15.16M | $15.11M | $15.07M |
| Total Liabilities | $36.13M | $38.68M | $37.98M | $40.73M | $38.34M | $37.77M | $37.38M | $40.00M | $40.19M | $40.98M |
| Stockholders' Equity | $21.40M | $32.08M | $43.25M | $54.91M | $66.54M | $77.65M | $56.02M | $66.27M | $75.13M | $20.25M |
| Retained Earnings | ($594.49M) | ($582.44M) | ($569.36M) | ($555.80M) | ($542.23M) | ($529.35M) | ($516.83M) | ($504.62M) | ($493.98M) | ($483.11M) |
Cash Flow
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($14.34M) | - | - | - | ($12.37M) | - | - | - |
| Investing Cash Flow | - | - | ($194.0K) | - | - | - | $32.62M | - | - | - |
| Financing Cash Flow | - | - | $0 | - | - | - | $1.0K | - | - | - |
| CapEx | - | - | $194.0K | - | - | - | $130.0K | - | - | - |
| Free Cash Flow | - | - | ($14.54M) | - | - | - | ($12.50M) | - | - | - |
Ratios
| Metric | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | -300.0% | -155.6% | - | -278.0% | -5010.0% |
| Operating margin | - | - | - | - | - | -34660.0% | -13158.9% | - | -21036.0% | -111200.0% |
| EBITDA margin | - | - | - | - | - | - | -12913.3% | - | - | - |
| Net margin | - | - | - | - | - | -35748.6% | -13566.7% | - | -21734.0% | -114540.0% |
| Free cash flow margin | - | - | - | - | - | - | -13885.6% | - | - | - |
| FCF / Net income | - | - | 1.07 | - | - | - | 1.02 | - | - | - |
| R&D / Revenue | - | - | - | - | - | 23877.1% | 8511.1% | - | 14032.0% | 69350.0% |
| SG&A / Revenue | - | - | - | - | - | 10482.9% | 4492.2% | - | 6726.0% | 36840.0% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -20.9% | -18.5% | -16.7% | - | -12.3% | -10.8% | -13.1% | - | -9.4% | -18.7% |
| Return on equity | -56.3% | -40.8% | -31.3% | - | -19.4% | -16.1% | -21.8% | - | -14.5% | -56.6% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.74 | 4.83 | 6.61 | 6.52 | 9.17 | 11.25 | 7.19 | 8.07 | 8.97 | 3.76 |
| Quick ratio | 1.74 | 4.83 | 6.61 | 6.52 | 9.17 | 11.25 | 7.14 | 8.05 | 8.97 | 3.76 |
| Cash ratio | 1.59 | 4.56 | 6.26 | 6.28 | 8.40 | 9.64 | 4.77 | 2.80 | 5.00 | 2.83 |
| Leverage | ||||||||||
| Debt / Equity | 0.00 | 0.49 | 0.37 | 0.29 | 0.24 | 0.20 | 0.24 | 0.23 | 0.20 | 0.74 |
| Debt / Assets | 0.00 | 0.22 | 0.20 | 0.17 | 0.15 | 0.14 | 0.14 | 0.14 | 0.13 | 0.25 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 2.69 | 2.21 | 1.88 | 1.74 | 1.58 | 1.49 | 1.67 | 1.60 | 1.53 | 3.02 |
| Liabilities / Assets | 0.63 | 0.55 | 0.47 | 0.43 | 0.37 | 0.33 | 0.40 | 0.38 | 0.35 | 0.67 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | 0.00 | 0.00 | - | - | 0.00 | 0.00 | - | 0.00 | 0.00 |
| Inventory turnover | - | - | - | - | - | - | 0.51 | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | 722d | - | - | - |
| Days payable outstanding | - | - | - | - | - | 3282d | 909d | - | 985d | 475d |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | -100.0% | -100.0% | - | - | 250.0% | -43.8% | - | -60.0% | -94.7% |
| Revenue CAGR (3y) | - | - | - | - | - | -52.5% | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | 79.0% | -159.3% | - | -46.3% | -3753.8% |
| Operating income growth (YoY) | 5.1% | -5.1% | -11.1% | - | -18.6% | -9.1% | -2.4% | - | -4.6% | 5.9% |
| Net income growth (YoY) | 6.5% | -4.5% | -11.0% | - | -18.5% | -9.2% | -3.8% | - | -8.2% | 2.3% |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | -16.3% | - | - | - | -2.8% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -67.8% | -58.7% | -22.8% | -17.1% | -11.4% | 283.5% | 87.1% | 64.7% | 48.4% | -65.7% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing OTONOMY against the 5 most active filers in the same SIC group.